Surgical Science Sweden AB (publ) (STO:SUS)
Sweden · Delayed Price · Currency is SEK 51.10
-0.70 (-1.35%)
Sep 4, 2026, 5:29 PM CET
STO:SUS Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,022 | 992.34 | 884.09 | 882.85 | 802.54 | 366.78 | |
Revenue Growth | 8.40% | 12.25% | 0.14% | 10.01% | 118.81% | 249.98% |
Cost of Revenue | 342.55 | 334.67 | 286.19 | 269.97 | 271.02 | 100.84 |
Gross Profit | 679.94 | 657.68 | 597.9 | 612.88 | 531.52 | 265.94 |
Selling, General & Admin | 287.76 | 298.7 | 252.38 | 240.02 | 201.88 | 117.26 |
Research & Development | 231.93 | 222.11 | 196.11 | 181.57 | 172.79 | 65.71 |
Other Operating Expenses | 5.29 | 5.29 | 5.19 | 2.14 | - | - |
Operating Expenses | 524.98 | 526.09 | 453.68 | 423.73 | 374.66 | 182.97 |
Operating Income | 154.97 | 131.58 | 144.22 | 189.15 | 156.86 | 82.98 |
Interest Expense | -4.65 | -6.15 | -5.55 | -0.64 | -0.54 | -0.51 |
Interest & Investment Income | 13.12 | 17.82 | 23.96 | 64.73 | - | - |
Currency Exchange Gain (Loss) | -35.76 | -39.98 | 0.07 | 15.04 | 5.68 | -6.02 |
Other Non Operating Income (Expenses) | -17.43 | -0.13 | -0.41 | -0.02 | 46.17 | 18.06 |
EBT Excluding Unusual Items | 110.25 | 103.14 | 162.29 | 268.26 | 208.17 | 94.5 |
Merger & Restructuring Charges | 12.9 | -5.9 | -4.2 | - | - | -28.7 |
Other Unusual Items | 2.9 | 2.9 | - | - | - | - |
Pretax Income | 126.05 | 100.14 | 158.09 | 268.26 | 208.17 | 65.8 |
Income Tax Expense | 32.91 | 33.32 | 26.45 | 34.29 | 20.2 | -20.44 |
Net Income | 93.14 | 66.82 | 131.65 | 233.97 | 187.97 | 86.25 |
Net Income to Common | 93.14 | 66.82 | 131.65 | 233.97 | 187.97 | 86.25 |
Net Income Growth | 0.74% | -49.24% | -43.73% | 24.47% | 117.95% | 452.66% |
Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | 42 |
Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | 43 |
Shares Change | - | - | 0.17% | 0.05% | 19.32% | 24.14% |
EPS (Basic) | 1.83 | 1.31 | 2.58 | 4.59 | 3.70 | 2.03 |
EPS (Diluted) | 1.82 | 1.31 | 2.58 | 4.59 | 3.69 | 2.02 |
EPS Growth | 0.55% | -49.24% | -43.79% | 24.39% | 82.67% | 348.89% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 124.11 | 68.12 | 131.12 | 227.84 | 120.14 | 35.21 |
Free Cash Flow Per Share | 2.43 | 1.33 | 2.57 | 4.47 | 2.36 | 0.82 |
Gross Margin | 66.50% | 66.27% | 67.63% | 69.42% | 66.23% | 72.51% |
Operating Margin | 15.16% | 13.26% | 16.31% | 21.43% | 19.55% | 22.62% |
Profit Margin | 9.11% | 6.73% | 14.89% | 26.50% | 23.42% | 23.52% |
Free Cash Flow Margin | 12.14% | 6.86% | 14.83% | 25.81% | 14.97% | 9.60% |
EBITDA | 184.4 | 159.11 | 169.55 | 212.15 | 177.47 | 99 |
EBITDA Margin | 18.03% | 16.03% | 19.18% | 24.03% | 22.11% | 26.99% |
D&A For EBITDA | 29.43 | 27.52 | 25.33 | 23 | 20.61 | 16.02 |
EBIT | 154.97 | 131.58 | 144.22 | 189.15 | 156.86 | 82.98 |
EBIT Margin | 15.16% | 13.26% | 16.31% | 21.43% | 19.55% | 22.62% |
Effective Tax Rate | 26.11% | 33.27% | 16.73% | 12.78% | 9.70% | - |